ANTERIS TECHNOLOGIES GLOBAL
AVRNASDAQTrading Snapshot
- Day Range
- $7.53 – $7.69
- 52-Week Range
- $3.30 – $11.06
- Volume
- $3.12B
- Avg Volume
- $2.65B
- Shares Outstanding
- 97.3M
- Next Earnings
- Oct 27, 2026
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $1M
- P/E Ratio
- —
- P/S Ratio
- 334.3x
- EPS (TTM)
- $-1.93
- Dividend Yield
- —
- Dilution (1yr)
- +0.0%
Why Investors Own AVR
- ✓High-growth profile — revenue up +11.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 77% gross margin and 12% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ANTERIS TECHNOLOGIES GLOBAL
AVR
StockOtter · stockotter.spaceAbout ANTERIS TECHNOLOGIES GLOBAL
Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds. These bioscaffolds are designed to simulate human tissue for various surgical repairs, notably in aortic valve replacement. Additionally, the ComASUR delivery system, a physician-designed balloon-expandable apparatus, features a reinforced, steerable catheter. This allows for highly accurate navigation through cardiac anatomy in a controlled manner, thereby mitigating potential damage to the aorta. Founded in 1999, Anteris Technologies Global Corp. operates out of Toowong, Australia.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Anteris Technologies appoints Brent Moen as chief financial officer
Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has appointed experienced financial executive Brent Moen as chief financial officer, effective September...
BlackRock Inc. Acquires Shares of 5,771,213 Anteris Technologies Global Corp. $AVR
BlackRock Inc. bought a new position in shares of Anteris Technologies Global Corp. (NASDAQ: AVR) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC
Anteris to Present at September Healthcare Investor Conferences
MINNEAPOLIS and BRISBANE, Australia, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing, developing
ADAR1 Capital Management LLC Acquires New Position in Anteris Technologies Global Corp. $AVR
ADAR1 Capital Management LLC bought a new position in shares of Anteris Technologies Global Corp. (NASDAQ: AVR) during the second quarter, according to the company in its most recent 13F filing with the Securities and Ex
Assenagon Asset Management S.A. Invests $6.35 Million in Anteris Technologies Global Corp. $AVR
Assenagon Asset Management S.A. bought a new stake in Anteris Technologies Global Corp. (NASDAQ: AVR) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange
Anteris Technologies Announces Results for the Second Quarter of 2026
MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing, developing